Brief: Ryvu Therapeutics Reaches Second Milestone Under License Agreement With Exelixis
Feb 5 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* REACHES SECOND MILESTONE UNDER LICENSE AGREEMENT WITH
EXELIXIS
* UNDER AGREEMENT COMPANY IS ELIGIBLE TO GET $2 MILLION OF
REMUNERATION FOR ACHIEVING SECOND MILESTONE
* AGREEMENT TO DEVELOP TARGETED THERAPIES USING COMPANY-MADE
STING
TECHNOLOGY
Source text for Eikon: ID:nEMbB6tpna
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys